ERBB2 and breast carcinoma: Lapatinib, a reversible TKI, is one of them and is typically used in conjunction with capecitabine to treat advanced or metastatic breast cancers that exhibit HER2 overexpression and have previously been treated with anthracycline, paclitaxel, or Herceptin (Paul et al., 2008).